Blood disorders
Lymphoma in Wuhan
武汉 淋巴瘤
4 hospitals in Wuhan
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Wuhan may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 65 papers led
- 46 papers led
- 14 papers led
- 3 papers ledNo open trial led
Lymphoma in every city Wuhan on the disease page, with the national map
open trials on lymphoma with a hospital in Wuhan
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Wuhan as lead sponsor or study site. 12 of them are led by a hospital in Wuhan. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingPIC1 Injection Therapy for Relapsed/Refractory B-NHL
- Phase
- Phase 1
- Started
- 2026-03
- Posted
- Registry
- NCT07456371
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07496229
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07548697
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07823829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06689917
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06820268
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingHypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06867536
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingClinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-03
- Posted
- Registry
- NCT06909474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06911502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07053670
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 1 listed hospital as study siteShanghai, Wuhan
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07101705
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingKSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07260812
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan
- RecruitingRandomised Controlled Trial of Artificial Intelligence-assisted Health Education
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07305337
Age 18 years to 90 years (registered criteria)
Led by Zhongnan Hospital of Wuhan UniversityWuhan
- RecruitingA Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07350850
Age 18 years to Not stated (registered criteria)
Led by Tongji Hospital; 2 listed hospitals as study sitesChangchun, Fuzhou, Wuhan
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingRD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies
- Phase
- Phase 1
- Started
- 2024-10
- Posted
- Registry
- NCT06732492
Age 3 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingCD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06735495
Age 3 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingThe Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2023-04
- Posted
- Registry
- NCT05741359
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Wuhan
- RecruitingProspective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05976997
Age 18 years to 70 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingAn Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Phase
- Early phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06693973
Age 18 years to Not stated (registered criteria)
Led by Union HospitalWuhan
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingZanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT06005870
Age 18 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingFirst in Human, Dose Escalation Study of AN4005
- Phase
- Phase 1
- Started
- 2021-09
- Posted
- Registry
- NCT04999384
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan
- RecruitingStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 2
- Started
- 2021-12
- Posted
- Registry
- NCT05147467
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingClinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07345741
Age 18 years to 78 years (registered criteria)
Led by Tongji HospitalWuhan
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Wuhan
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Hubei University of Chinese Medicine湖北省中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Puren Hospital of Wuhan University of Science and Technology武汉市普仁医院 | 5 | none | none | none | none | none | none | none | none | 1 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Asia Heart Hospital武汉亚洲心脏病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Central Hospital, Tongji Medical College武汉市中心医院 | none | none | none | none | none | none | 19 | none | none | 2 | none | 3 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 15 | none | none | none | none | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Central Theater General Hospital中部战区总医院 | none | none | none | none | none | none | none | none | none | 2 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Child Health Hospital, Tongji Medical College湖北省妇幼保健院 | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | 2 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Geriatric Hospital, Wuhan University of Science武汉科技大学附属老年病医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guanggu Hospital武汉光谷医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hospital, Wuhan University of Science武汉科技大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Huangpi District People's Hospital黄陂区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hubei Cancer Hospital湖北省肿瘤医院 | 13 | 1 | 8 | 8 | 414 open | 6 | 457 open | none | none | none | none | 1 | 1 | 0 | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hubei Provincial Hospital湖北省人民医院 | none | none | 6 | none | none | none | none | none | none | 1 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Liyuan Hospital梨园医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| People's Hospital, Jianghan University湖北省第三人民医院 | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | |
| Renmin Hospital of Wuhan University武汉大学人民医院 | 13 | 122 open | 87 | 741 open | 74 | 29 | 68 | 61 | none | 5 | none | 31 | 2 | 10 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 18 | 4 | none | 1 | none | none | 1 | none | 3 | none | none | none | none | 2 | 0 | 2 | none | none | none | 1 | none | none | none | none | none | 2 | 2 | none | none | none | |
| Second Affiliated Hospital of Jianghan University武汉市第五医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tianyou Hospital武汉科技大学附属天佑医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tongji Hospital华中科技大学同济医学院附属同济医院 | 8 | 102 open | 23823 open | 454 open | 1478 open | 666 open | 1165 open | 70 | 0 | 1 | 1 | 12 | 31 open | 8 | 0 | 193 open | 71 open | 8 | 201 open | 653 open | 0 | 4 | none | 6 | none | 187 open | 112 open | 178 open | 31 open | none | 21 open | 261 open | 14 | 7 | 2 | none | none | 14 | 1 | 111 open | none | 0 | none | 2 | 1 | 2 | 21 | 0 | 0 | 0 | 2 | none | none | 13 | 0 | 1 | 0 | 2 | none | none | none | |
| Union Hospital华中科技大学同济医学院附属协和医院 | 111 open | 81 open | 1446 open | 789 open | 17618 open | 706 open | 957 open | 612 open | 1 | 2 | 1 | 25 | 18 | 8 | 2 | 305 open | 32 open | 21 open | 8 | 468 open | none | 1 | none | none | 1 | 1 | 0 | 01 open | 2 | none | 7 | 411 open | 40 | 3 | 2 | 1 | none | 3 | none | 0 | none | none | none | none | 0 | none | 21 open | none | none | 1 | 3 | 0 | 1 | 8 | none | none | 0 | none | none | none | none | |
| Union Jiangnan Hospital, Huazhong University of Science武汉市江夏区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Union Wuhan Red Cross Hospital武汉市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| WISCO General Hospital华润武钢总医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuchang Eyegood Ophthalmic Hospital武汉武昌艾格眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuchang Hospital, Wuhan University of Science武汉市武昌医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Aier Eye Hospital武汉爱尔眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asia General Hospital武汉亚心总医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asia Heart Hospital武汉亚洲心脏病医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 15 | 26 | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Asian Heart Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Children's Hospital武汉市儿童医院 | none | none | none | none | none | none | 3 | none | none | 1 | none | 1 | none | 1 | none | none | 1 | 0 | none | none | 1 | none | 1 | none | none | none | none | none | none | none | none | none | 8 | none | 0 | none | none | none | none | none | 1 | 0 | none | 1 | 1 | 1 | none | none | none | none | none | none | none | 0 | none | none | none | 1 | 1 | none | none | |
| Wuhan Fourth Hospital武汉市第四医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan General Hospital中国人民解放军广州军区武汉总医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Hanyang Hospital武汉市汉阳医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Hospital, Tongji Medical College武汉市中西医结合医院(武汉市第一医院) | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Jinyintan Hospital武汉市金银潭医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Third Hospital武汉市第三医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Tongji Reproductive Medicine Hospital武汉同济生殖医学专科医院 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan University Hospital武汉大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wuhan Xinzhou District People's Hospital武汉市新洲区人民医院 | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongnan Hospital of Wuhan University武汉大学中南医院 | 11 | 2 | 97 | 292 open | 1054 open | 21 | 814 open | 721 open | none | 2 | none | 19 | 1 | 6 | 1 | 123 open | none | 2 | none | 141 open | none | none | none | none | 2 | none | none | none | 13 | none | none | 12 | 5 | 2 | 2 | 1 | none | 6 | 0 | 1 | none | none | none | 1 | 2 | none | 1 | none | none | none | 0 | 1 | none | none | none | none | 1 | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Wuhan.
- Nasopharyngeal carcinoma 13
- Oesophageal squamous cell carcinoma 122 open
- Hepatocellular carcinoma 87
- Stomach cancer 741 open
- Lung cancer 74
- Pancreatic cancer 29
- Breast cancer 68
- Glioma 61
- Retinoblastoma 5
- Osteosarcoma 31
- Gastrointestinal stromal tumour 2
- Neuroblastoma 10
- Ewing sarcoma 1
- Myasthenia gravis 0
- Coronary heart disease 18
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 3
- Behçet disease 2
- Alport syndrome 0
- IgA nephropathy 2
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 2
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 102 open
- Hepatocellular carcinoma 23823 open
- Stomach cancer 454 open
- Lung cancer 1478 open
- Pancreatic cancer 666 open
- Breast cancer 1165 open
- Glioma 70
- Hepatoblastoma 0
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 12
- Gastrointestinal stromal tumour 31 open
- Neuroblastoma 8
- Ewing sarcoma 0
- Multiple myeloma 193 open
- B-cell acute lymphoblastic leukaemia 71 open
- Aplastic anaemia 8
- Haemophagocytic lymphohistiocytosis 201 open
- Lymphoma 653 open
- Beta thalassaemia 0
- Haemophilia A 4
- Thrombotic thrombocytopenic purpura 6
- Neuromyelitis optica spectrum disorder 187 open
- IgG4-related disease 112 open
- Myasthenia gravis 178 open
- Moyamoya disease 31 open
- Biliary atresia 21 open
- Coronary heart disease 261 open
- Congenital heart disease 14
- Scoliosis 7
- Anti-NMDA receptor encephalitis 2
- Idiopathic pulmonary fibrosis 14
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 111 open
- Fabry disease 0
- Duchenne muscular dystrophy 2
- Behçet disease 1
- Alport syndrome 2
- IgA nephropathy 21
- Gaucher disease 0
- Niemann–Pick disease type C 0
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 2
- Hirschsprung disease 13
- Inherited epidermolysis bullosa 0
- Hereditary angioedema 1
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 111 open
- Oesophageal squamous cell carcinoma 81 open
- Hepatocellular carcinoma 1446 open
- Stomach cancer 789 open
- Lung cancer 17618 open
- Pancreatic cancer 706 open
- Breast cancer 957 open
- Glioma 612 open
- Hepatoblastoma 1
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 25
- Gastrointestinal stromal tumour 18
- Neuroblastoma 8
- Ewing sarcoma 2
- Multiple myeloma 305 open
- B-cell acute lymphoblastic leukaemia 32 open
- Aplastic anaemia 21 open
- Haemophagocytic lymphohistiocytosis 8
- Lymphoma 468 open
- Haemophilia A 1
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 1
- IgG4-related disease 0
- Myasthenia gravis 01 open
- Moyamoya disease 2
- Biliary atresia 7
- Coronary heart disease 411 open
- Congenital heart disease 40
- Scoliosis 3
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 3
- Amyotrophic lateral sclerosis 0
- Behçet disease 0
- IgA nephropathy 21 open
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 8
- Familial adenomatous polyposis 0
- Breast cancer 3
- Retinoblastoma 1
- Osteosarcoma 1
- Neuroblastoma 1
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 0
- Beta thalassaemia 1
- Atypical haemolytic uraemic syndrome 1
- Congenital heart disease 8
- Anti-NMDA receptor encephalitis 0
- Spinal muscular atrophy 1
- Fabry disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- Alport syndrome 1
- Hirschsprung disease 0
- Leber hereditary optic neuropathy 1
- Majeed syndrome 1
- Nasopharyngeal carcinoma 11
- Oesophageal squamous cell carcinoma 2
- Hepatocellular carcinoma 97
- Stomach cancer 292 open
- Lung cancer 1054 open
- Pancreatic cancer 21
- Breast cancer 814 open
- Glioma 721 open
- Retinoblastoma 2
- Osteosarcoma 19
- Gastrointestinal stromal tumour 1
- Neuroblastoma 6
- Ewing sarcoma 1
- Multiple myeloma 123 open
- Aplastic anaemia 2
- Lymphoma 141 open
- Fanconi anaemia 2
- Moyamoya disease 13
- Coronary heart disease 12
- Congenital heart disease 5
- Scoliosis 2
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 6
- Lymphangioleiomyomatosis 0
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Behçet disease 2
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Wuhan on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.